Health Canada Approves Keytruda Combo for Bladder Cancer, Expanding Market
MRK sits 68% above its 52-week low of $77.58 on light trading volume (0.2× avg).
Summary
Health Canada approved Keytruda plus enfortumab vedotin for muscle-invasive bladder cancer patients ineligible for cisplatin, as neoadjuvant and adjuvant therapy. This follows the FDA's July 10 approval of the same combination, extending the label into a new major market. The Canadian approval specifies the neoadjuvant/adjuvant setting and cisplatin-ineligible population, broadening the addressable patient base. Keytruda remains Merck's flagship oncology franchise, and incremental regulatory wins reinforce its growth trajectory. The news comes a day after strong Q2 results and raised guidance, adding to positive momentum.
At the time of this announcement, MRK was trading at $130.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $322.9B. The 52-week trading range was $77.58 to $135.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.